Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evobrutinib Phase II in SLE
NCT02975336Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Jan 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of evobrutinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by EMD Serono. Primary endpoints: Systemic Lupus Erythematosus Responder Index 4 at 52 weeks, Systemic Lupus Erythematosus Responder Index 6 at 52 weeks and 3 more. Started Jan 2017; status: terminated.
02
Drugs
evobrutinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02975336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02975336.